La Jolla Pharmaceutical Company – Consensus Indicates Potential 138.7% Upside

Broker Ratings

La Jolla Pharmaceutical Company with ticker code (LJPC) have now 3 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 20 and 4 with the average target price sitting at 10.67. Now with the previous closing price of 4.47 this indicates there is a potential upside of 138.7%. The 50 day moving average now sits at 4.48 and the 200 day MA is 4.33. The company has a market capitalisation of $120m. You can visit the company’s website by visiting:

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. It is also developing LJPC-0118 for the treatment of severe malaria; and LJPC-401 (synthetic human hepcidin), an investigational product to treat conditions characterized by iron overload. The company was founded in 1989 and is headquartered in San Diego, California.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits
Find more news, interviews, share price & company profile here for:

    Good news travels fast (but only if you make that happen). Share on:


      AIM All Share Index